Kronos Bio, Inc. (NASDAQ:KRON) Short Interest Up 16.5% in December

Kronos Bio, Inc. (NASDAQ:KRON) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 577,700 shares, an increase of 16.5% from the December 15th total of 496,000 shares. Approximately 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 255,900 shares, the days-to-cover ratio is currently 2.3 days.

Hedge Funds Weigh In On Kronos Bio

An institutional investor recently raised its position in Kronos Bio stock. Forefront Analytics LLC increased its position in Kronos Bio, Inc. (NASDAQ:KRON) by 75.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 134,998 shares of the company’s stock after buying an additional 57,867 shares during the quarter. Forefront Analytics LLC owned 0.22% of Kronos Bio worth $167,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 64.09% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on KRON shares. TD Cowen downgraded Kronos Bio from a “buy” rating to a “hold” rating in a research note on Thursday, November 14th. Piper Sandler lowered shares of Kronos Bio from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $6.00 to $1.00 in a report on Thursday, November 14th.

Kronos Bio Trading Down 1.9 %

Shares of KRON opened at $0.99 on Friday. Kronos Bio has a 52 week low of $0.69 and a 52 week high of $1.60. The stock has a fifty day moving average of $0.95 and a 200-day moving average of $1.02.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.